Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Epstein-Barr Viral Infections-Pipeline Review, H1 2015

Epstein-Barr Viral Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Epstein-Barr Viral Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Epstein-Barr Viral Infections-Pipeline Review, H1 2015', provides an overview of the Epstein-Barr Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epstein-Barr Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epstein-Barr Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Epstein-Barr Viral Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Epstein-Barr Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Epstein-Barr Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Epstein-Barr Viral Infections Overview 7

Therapeutics Development 8

Pipeline Products for Epstein-Barr Viral Infections-Overview 8

Pipeline Products for Epstein-Barr Viral Infections-Comparative Analysis 9

Epstein-Barr Viral Infections-Therapeutics under Development by Companies 10

Epstein-Barr Viral Infections-Therapeutics under Investigation by Universities/Institutes 11

Epstein-Barr Viral Infections-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Epstein-Barr Viral Infections-Products under Development by Companies 15

Epstein-Barr Viral Infections-Products under Investigation by Universities/Institutes 16

Epstein-Barr Viral Infections-Companies Involved in Therapeutics Development 17

Cell Medica Limited 17

Epiphany Biosciences, Inc. 18

Theravectys S.A. 19

ViroStatics, srl 20

Epstein-Barr Viral Infections-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

Cell Therapy 2 for Oncology and Infectious Disease-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Cell Therapy for Infectious Disease-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Cell Therapy for Infectious Diseases-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Cell Therapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CMD-003-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

EBV vaccine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

EBV vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Peptide for EBV Infections-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Inhibit CDK9 for EBV and HSV Infections-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for EBV Infections-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules for Viral Infections-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules to Inhibit EBNA1 for EBV Latent Infection-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Vaccine for EBV Associated Nasopharyngeal Cancer-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

valomaciclovir stearate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Epstein-Barr Viral Infections-Recent Pipeline Updates 51

Epstein-Barr Viral Infections-Dormant Projects 52

Epstein-Barr Viral Infections-Product Development Milestones 53

Featured News & Press Releases 53

Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus 53

Nov 08, 2011: Protection against Epstein-Barr virus: new approach towards an effective vaccine 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

Number of Products under Development for Epstein-Barr Viral Infections, H1 2015 8

Number of Products under Development for Epstein-Barr Viral Infections-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Epstein-Barr Viral Infections-Pipeline by Cell Medica Limited, H1 2015 17

Epstein-Barr Viral Infections-Pipeline by Epiphany Biosciences, Inc., H1 2015 18

Epstein-Barr Viral Infections-Pipeline by Theravectys S.A., H1 2015 19

Epstein-Barr Viral Infections-Pipeline by ViroStatics, srl, H1 2015 20

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 23

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Epstein-Barr Viral Infections Therapeutics-Recent Pipeline Updates, H1 2015 51

Epstein-Barr Viral Infections-Dormant Projects, H1 2015 52

List of Figures

Number of Products under Development for Epstein-Barr Viral Infections, H1 2015 8

Number of Products under Development for Epstein-Barr Viral Infections-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Top 10 Targets, H1 2015 22

Number of Products by Stage and Top 10 Targets, H1 2015 23

Number of Products by Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cell Medica Limited

Epiphany Biosciences, Inc.

Theravectys S.A.

ViroStatics, srl

Epstein-Barr Viral Infections Therapeutic Products under Development, Key Players in Epstein-Barr Viral Infections Therapeutics, Epstein-Barr Viral Infections Pipeline Overview, Epstein-Barr Viral Infections Pipeline, Epstein-Barr Viral Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com